Page URL:

Trial opens to test Alzheimer's prevention in genetically at-risk patients

15 October 2012
Appeared in BioNews 677

Up to three experimental drugs will be tested to determine if they can be used to prevent the development of Alzheimer's disease. The clinical trials, which are due to start in 2013, will include people at genetic risk of the early-onset form of the disease. Unusually, these trials will focus on preventative treatment, hoping to halt or slow the onset of symptoms, rather than taking the traditional approach of treating symptoms after they develop.

'Trying to prevent Alzheimer's symptoms from ever occurring is a new strategy', says Dr John Morris, the principal investigator at the Dominantly Inherited Alzheimer's Network (DIAN) at the Washington University School of Medicine, USA, which is conducting the trials. There is currently no cure for Alzheimer's disease, and therapies to treat symptoms have had little success so far.

The trials will include two drugs already shown to have some effect on Alzheimer's symptoms. These are gantenerumab, developed by Roche, and solanezumab, developed by Eli Lilly and Company. Potentially, a third drug, a beta secretase inhibitor, also developed by Lilly, may be included.

All three drugs target amyloid beta, the main component of plaques that typically form in the brains of people with Alzheimer's, but in different ways.

'We are excited that this diverse portfolio of drugs and approaches will accelerate the discovery of an effective treatment for Alzheimer's', says Randall Bateman, professor in neurology at Washington University School of Medicine, who is involved in the trials.

The trials will include 160 people carrying early-onset Alzheimer's mutations, but who currently have little or no symptoms of the disease. The early-onset inherited form is not the most common type of Alzheimer's, but people with these mutations are very likely to develop the disease, compared to the general population. Symptoms typically start showing around 30 to 50 years old, and the people chosen to participate in the trial will be within ten to 15 years of their anticipated onset.

Each person will receive one of the three drugs, or a placebo, and they will be monitored for known early biological indicators of Alzheimer's development. Initial trials are expected to last for two years, but will continue and expand if any drug succeeds in halting or significantly slowing the build-up of these biological indicators.

Trials will be conducted in DIAN trial sites around the world, including Europe and Australia.

Investigational drugs chosen for major Alzheimer’s prevention trial
Washington University in St Louis (press release) |  10 October 2012
Lilly, Roche Drugs Chosen for Alzheimer Prevention Trial
Bloomberg |  10 October 2012
Roche, Lilly drugs set for Alzheimer's prevention trial
Reuters |  10 October 2012
Wash. U. Researchers Hope Drug Cures Alzheimer’s Disease
Fox2 Now |  11 October 2012
4 November 2013 - by Dr Rachel Montgomery 
Eleven genetic variants linked to late-onset Alzheimer's disease have been found by the largest study on the genetics behind the condition to date...
18 February 2013 - by Michelle Downes 
Hormone replacement therapy, used to treat the symptoms of menopause, may play a role in slowing the ageing process in women who carry a certain gene variant, claim scientists...
19 November 2012 - by Helen Brooks 
A single genetic mutation increases the risk of developing Alzheimer’s disease by threefold, say scientists from two independent research groups...
16 July 2012 - by Dr Linda Wijlaars 
A rare genetic mutation, found in about one percent of Icelanders in a recent study, appears to protect against Alzheimer's disease and age-related cognitive decline. It is the first mutation found to act in this way and could be a target for future drug therapy...
18 June 2012 - by Dr Linda Wijlaars 
A gene known to be found in many Alzheimer's patients has been linked to the way insulin is processed in the body. The finding could prove there is a link between Alzheimer's disease and type 2 diabetes, explaining why people with diabetes face a higher risk of developing Alzheimer's....
11 April 2011 - by Alison Cranage 
International scientists including researchers at Cardiff University, UK and the University of Pennsylvania, USA have discovered five genetic variations associated with Alzheimer's disease. The findings are published in two papers in the journal Nature Genetics...
29 March 2010 - by Sarah Pritchard 
Researchers at the University of California San Francisco are about to begin a groundbreaking new breast cancer trial designed to speed up the drugs discovery process and cut the delivery time of new personalised cancer therapies...
28 September 2009 - by Dr Jay Stone 
Dr R. Scott Turner and his team of the Memory Disorders Program at Georgetown University, US, have begun recruiting patients to take part in a gene therapy trial, which hopes to test whether gene therapy using the nerve growth factor (NGF) gene could be used to slow the progression of Alzheimer's disease...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.